Skip to content
Study details
Enrolling now

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

University of Hawaii
NCT IDNCT06935838ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

12

Study length

about 9 months

Ages

18+

Locations

1 site in HI

About this study

This trial is testing whether tirzepatide helps with weight loss and reduces chronic inflammation in people living with HIV. Participants will receive tirzepatide, a medication, for 261 days. It aims to measure changes in weight, body composition, liver health, inflammatory markers, and other factors.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Tirzepatide
PhasePhase 2
DrugTirzepatide
Routeinjection
Primary goalChange in Baseline Body Weight

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

tirzepatide

Drug routes

injection (Injection)

Endpoints

Primary: Change in Baseline Body Weight

Secondary: Body composition, Change in Inflammatory Markers: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, Waist circumference

Body systems

Immune, Infectious